This is forget a share never HCCF
ere it is
HEE Corporation Announces Heart-Healthy Metobolic Product
Thursday May 19, 9:43 am ET
HPB-Artery Klenz to serve as an oral supplement for heart disease.
HUTCHINSON, Kan., May 19 /PRNewswire-FirstCall/ -- HEE Corporation Inc. (OTC Bulletin Board: HCCF - News) announced today the acquisition of a natural oral chelate, or detoxifying agent, designed to inhibit and repair the damaging effects of heart disease. Tentatively named "HPB-Artery Klenz," the metabolic product is intended to offer a preventative solution to cardiovascular dysfunction and provide a potential alternative to coronary bypass surgery.
Approximately 40 million Americans suffer from heart disease and nearly 300,000 undergo coronary artery bypass surgery every year. According to HEE Corporation President Radley Brooks, "The addition of Artery Klenz to our product mix will allow the consumer a safe and inexpensive formula for dealing with potential heart disease both before and after it becomes problematic and will help minimize the need for invasive surgical procedures."
Manufactured in the United States, HPB-Artery Klenz, "not only has the ability to remove calcium and plaque deposits from narrowed blood vessels, but will also improve metabolic and circulatory functions by removing various toxic metals such as iron, lead, mercury and cadmium," said Brooks.
Chelation is a metabolic medical treatment that has the capability of reducing high blood pressure and cholesterol, at the same time helping to eliminate arterial plaque, not only in the heart, but throughout the body. Working in concert with traditional medical techniques and remedies, HPB- Artery Klenz shows promise in making significant strides in the prevention and repair of the damaging effects of heart disease.
In April, HEE Corporation announced the launch of its web-based product sales and information site, . The exclusive international distributor of HPB-84, a nutriceutical developed in India, HEE Corporation has spent the past year testing and developing the promising nutriceutical for Type II diabetes. Similarly, HEE Corporation will conduct a thorough testing of HPB-Artery Klenz as the next addition to its product mix of natural products developed for metabolic syndrome. At the conclusion of such scientifically stringent testing, HPB-Artery Klenz will join the HEE Corporation family of naturopathic metabolic remedies for the treatment of catastrophic diseases.
About HEE
HEE's headquarters is based in Hutchinson, Kansas.
Forward-Looking Statements:
Advertisements
AI
